EP1633759B1 - Antibiotiques renfermant un compose reticule a base de glycopeptides et de cephalosporine - Google Patents

Antibiotiques renfermant un compose reticule a base de glycopeptides et de cephalosporine Download PDF

Info

Publication number
EP1633759B1
EP1633759B1 EP04752930A EP04752930A EP1633759B1 EP 1633759 B1 EP1633759 B1 EP 1633759B1 EP 04752930 A EP04752930 A EP 04752930A EP 04752930 A EP04752930 A EP 04752930A EP 1633759 B1 EP1633759 B1 EP 1633759B1
Authority
EP
European Patent Office
Prior art keywords
compound
hydrogen
formula
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04752930A
Other languages
German (de)
English (en)
Other versions
EP1633759A1 (fr
Inventor
Paul R. Fatheree
Martin S. Linsell
Daniel Marquess
Daniel D. Long
Jason P. Chinn
Matthew B. Nodwell
Edmund J. Moran
James B. Aggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of EP1633759A1 publication Critical patent/EP1633759A1/fr
Application granted granted Critical
Publication of EP1633759B1 publication Critical patent/EP1633759B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention is directed to novel cross-linked vancomycin - cephalosporin compounds which are useful as antibiotics.
  • This invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds as antibacterial agents; and processes and intermediates for preparing such compounds.
  • antibiotic compounds include, for example, ⁇ -lactam antibiotics, such as cephalosporins, and glycopeptide antibiotics, such as vancomycin.
  • Cross-linked antibiotic compounds are also known in the art. See, for example, U.S. Patent No. 5,693,791, issued to W.L. Truett and entitled “Antibiotics and Process for Preparation”; WO 99/64049 A1, published on December 16, 1999 , and entitled “Novel Antibacterial Agents”.
  • WO 03/031449 A2 published on April 17, 2003 , and entitled "Cross-Linked Glycopeptide - Cephalosporin Antibiotics” discloses compounds having a glycopeptide group covalently linked to the oxime moiety of a cephalosporin group.
  • MRSA methicillin-resistant Staphylococci aureus
  • the present invention provides novel cross-linked glycopeptide - cephalosporin compounds that are useful as antibiotics.
  • the compounds of this invention have a unique chemical structure in which a glycopeptide group is covalently linked to a pyridinium moiety of a cephalosporin group.
  • compounds of this invention have been found to possess surprising and unexpected potency against Gram-positive bacteria including methicillin-resistant Staphylococci aureus (MRSA).
  • this invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein
  • the invention provides a compound of formula II : or a pharmaceutically acceptable salt thereof; wherein
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, including any of the particular embodiments discussed herein.
  • this invention is also directed to processes for preparing compounds of formula I or II or a salt thereof. Accordingly, in another of its method aspects, this invention provides a process for preparing a compound of formula I or a salt thereof; the process comprising reacting a compound of formula 1 or a salt, activated derivative, or protected derivative thereof, with a compound of formula 3 or 4 or a salt, activated derivative, or protected derivative thereof; to provide a compound of formula I or a salt thereof; wherein the compounds of formula 1 , 3 and 4 are as defined herein.
  • this invention provides a process for preparing a compound of formula I or a salt thereof; the process comprising reacting a compound of formula 2 or a salt, activated derivative, or protected derivative thereof; with a compound of formula 5 or a salt, activated derivative, or protected derivative thereof; to provide a compound of formula I or a salt thereof; wherein the compounds of formula 2 and 5 are as defined herein.
  • these processes further comprise the step of forming a pharmaceutically acceptable salt of a compound of formula I.
  • This invention is also directed to the product prepared by any of these processes.
  • This invention is also directed to a compound of formula I or II, or a pharmaceutically acceptable salt thereof, for use in therapy. Additionally, this invention is directed to the use of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament, including a medicament for treating a bacterial infection in a mammal.
  • This invention provides novel glycopeptide - cephalosporin compounds of formula I or II , or pharmaceutically acceptable salts thereof. These compounds have multiple chiral centers and, in this regard, the compounds are intended to have the stereochemistry shown.
  • the glycopeptide portion of the compound is intended to have the stereochemistry of the corresponding naturally-occurring glycopeptide (i.e., vancomycin, chloroorienticin A and the like).
  • the cephalosporin portion of the molecule is intended to have the stereochemistry of known cephalosporin compounds.
  • minor amounts of isomers having a different stereochemistry from that shown may be present in the compositions of this invention provided that the utility of the composition as a whole is not significantly diminished by the presence of such isomers.
  • the linking portion of the compounds of this invention may contain one or more chiral centers. Typically, this portion of the molecule will be prepared as a racemic mixture. If desired, however, pure stereoisomers (i.e., individual enantiomers or diastereomers) may be used or a stereoisomer-enriched mixture can be employed. All such stereoisomers and enriched mixtures are included within the scope of this invention.
  • compounds of this invention contain several acidic groups (i.e., carboxylic acid groups) and several basic groups (i.e., primary and secondary amine groups) and therefore, the compounds of formula I can exist in various salt forms. All such salt forms are included within the scope of this invention. Also, since the compounds of formula I contain a pyridinium ring, an anionic counterion for the pyridinium group may optionally be present including, but not limited to, halides, such as chloride; carboxylates, such as acetate; and the like.
  • alkyl refers to a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 10 carbon atoms. Representative alkyl groups include, by way of example, methyl, ethyl, n -propyl, isopropyl, n -butyl, sec -butyl, isobutyl, tert -butyl, n -pentyl, n -hexyl, n -heptyl, n- octyl, n -nonyl, n -decyl and the like.
  • alkylene refers to a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms. Representative alkylene groups include, by way of example, methylene, ethane-1,2-diyl ("ethylene"), propane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl and the like.
  • alkenyl refers to a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 10 carbon atoms. Representative alkenyl groups include, by way of example, ethenyl, n- propenyl, isopropenyl, n -but-2-enyl, n -hex-3-enyl and the like.
  • alkynyl refers to a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 10 carbon atoms. Representative alkynyl groups include, by way of example, ethynyl, n- propynyl, n -but-2-ynyl, n -hex-3-ynyl and the like.
  • aryl refers to a monovalent aromatic hydrocarbon having a single ring (i.e., phenyl) or fused rings (i.e., naphthalene). Unless otherwise defined, such aryl groups typically contain from 6 to 10 carbon ring atoms. Representative aryl groups include, by way of example, phenyl and naphthalene-1-yl, naphthalene-2-yl, and the like.
  • arylene refers to a divalent aromatic hydrocarbon having a single ring (i.e., phenylene) or fused rings (i.e., naphthalenediyl). Unless otherwise defined, such arylene groups typically contain from 6 to 10 carbon ring atoms. Representative arylene groups include, by way of example, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, naphthalene-1,5-diyl, naphthalene-2,7-diyl, and the like.
  • cycloalkyl refers to a monovalent saturated carbocyclic hydrocarbon group. Unless otherwise defined, such cycloalkyl groups typically contain from 3 to 10 carbon atoms. Representative cycloalkyl groups include, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • cycloalkylene refers to a divalent saturated carbocyclic hydrocarbon group. Unless otherwise defined, such cycloalkylene groups typically contain from 3 to 10 carbon atoms. Representative cycloalkylene groups include, by way of example, cyclopropane-1,2-diyl, cyclobutyl-1,2-diyl, cyclobutyl-1,3-diyl, cyclopentyl-1,2-diyl, cyclopentyl-1,3-diyl, cyclohexyl-1,2-diyl, cyclohexyl-1,3-diyl, cyclohexyl-1,4-diyl, and the like.
  • halo refers to fluoro, chloro, bromo and iodo.
  • heteroaryl refers to a monovalent aromatic group having a single ring or two fused rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heteroaryl groups typically contain from 5 to 10 total ring atoms.
  • heteroaryl groups include, by way of example, monovalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, triazole, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, indole, benzofuran, benzothiophene, benzimidazole, benzthiazole, quinoline, isoquinoline, quinazoline, quinoxaline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
  • heteroarylene refers to a divalent aromatic group having a single ring or two fused rings and containing at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur in the ring. Unless otherwise defined, such heteroarylene groups typically contain from 5 to 10 total ring atoms.
  • heteroarylene groups include, by way of example, divalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, triazole, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, indole, benzofuran, benzothiophene, benzimidazole, benzthiazole, quinoline, isoquinoline, quinazoline, quinoxaline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
  • heterocyclyl or “heterocyclic” refers to a monovalent or divalent saturated or unsaturated (non-aromatic) group having a single ring or multiple condensed rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heterocyclic groups typically contain from 2 to 9 total ring atoms.
  • heterocyclic groups include, by way of example, monovalent species of pyrrolidine, imidazolidine, pyrazolidine, piperidine, 1,4-dioxane, morpholine, thiomorpholine, piperazine, 3-pyrroline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
  • cephalosporin is used herein in its art-recognized manner to refer to a ⁇ -lactam ring system having the following general formula and numbering system: where R x and R y represent the remaining portion of the cephalosporin.
  • glycopeptide antibiotic or "glycopeptide” is used herein in its art-recognized manner to refer to the class of antibiotics known as glycopeptides or dalbahpeptides. See, for example, R. Nagarajan, "Glycopeptide Antibiotics", Marcel Dekker, Inc. (1994 ) and references cited therein.
  • Representative glycopeptides include vancomycin, A82846A (eremomycin), A82846B (chloroorienticin A), A82846C, PA-42867-A (orienticin A), PA-42867-C, PA-42867-D and the like.
  • vancomycin is used herein in its art-recognized manner to refer to the glycopeptide antibiotic known as vancomycin.
  • the point of attachment for the linking moiety is at the "C-terminus" of vancomycin.
  • cross-linked glycopeptide - cephalosporin antibiotics refers to covalent conjugation of a glycopeptide component to a cephalosporin component.
  • salts refers to a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime).
  • Such salts can be derived from pharmaceutically-acceptable inorganic or organic bases and from pharmaceutically-acceptable inorganic or organic acids.
  • Salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • Salts derived from pharmaceutically-acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, fumaric, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, nicotinic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p -toluenesulfonic and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • salt thereof refers to a compound formed when the hydrogen of an acid is replaced by a cation, such as a metal cation or an organic cation and the like (e.g., an NH 4 + cation and the like).
  • a cation such as a metal cation or an organic cation and the like (e.g., an NH 4 + cation and the like).
  • the salt is a pharmaceutically acceptable salt, although this is not required for salts of intermediate compounds which are not intended for administration to a patient.
  • terapéuticaally effective amount refers to an amount sufficient to effect treatment when administered to a patient in need of treatment.
  • treating refers to the treating or treatment of a disease or medical condition (such as a bacterial infection) in a patient, such as a mammal (particularly a human or a companion animal) which includes:
  • growth-inhibiting amount refers to an amount sufficient to inhibit the growth or reproduction of a microorganism or sufficient to cause death or lysis of the microorganism including gram-positive bacteria.
  • cell wall biosynthesis-inhibiting amount refers to an amount sufficient to inhibit cell wall biosynthesis in a microorganism including gram-positive bacteria.
  • leaving group refers to a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction.
  • representative leaving groups include chloro, bromo and iodo groups; and sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; activated ester groups, such as such as 7-azabenzotriazole-1-oxy and the like; acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
  • protected derivatives thereof refers to a derivative of the specified compound in which one or more functional groups of the compound are protected from undesired reactions with a protecting or blocking group.
  • Functional groups which may be protected include, by way of example, carboxylic acid groups, amino groups, hydroxyl groups, thiol groups, carbonyl groups and the like.
  • protecting groups for carboxylic acids include esters (such as a p -methoxybenzyl ester), amides and hydrazides; for amino groups, carbamates (such as tert -butoxycarbonyl) and amides; for hydroxyl groups, ethers and esters; for thiol groups, thioethers and thioesters; for carbonyl groups, acetals and ketals; and the like.
  • Such protecting groups are well-known to those skilled in the art and are described, for example, in T.W. Greene and G.M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999 , and references cited therein.
  • amino-protecting group refers to a protecting group suitable for preventing undesired reactions at an amino group.
  • Representative amino-protecting groups include, but are not limited to, tert -butoxycarbonyl (BOC), trityl (Tr), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), formyl, trimethylsilyl (TMS), tert-butyldimethylsilyl (TBS), and the like.
  • carboxy-protecting group refers to a protecting group suitable for preventing undesired reactions at an carboxy group.
  • Representative carboxy-protecting groups include, but are not limited to, esters, such as methyl, ethyl, tert -butyl, benzyl (Bn), p -methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBS), diphenylmethyl (benzhydryl, DPM) and the like.
  • an “activated derivative”, with respect to a carboxylic acid or protected derivative thereof, refers to the product, typically a reactive ester, resulting from reaction of the carboxylic acid or derivative with an activating (coupling) agent, such as, for example, 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azabenzotriazole (HOAT), or others described below or otherwise known in the art.
  • an activating (coupling) agent such as, for example, 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azabenzotriazole (HOAT), or others described below or otherwise known in the art.
  • a "side chain of a naturally occurring amino acid” refers to the group R in the formula HOOC-CHR-NH 2 , where this formula represents an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, and preferably selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, isoleucine, leucine, lysine, methionine, serine, threonine, and valine.
  • any heteroarylene or heterocyclic group present in R" preferably has 5 or 6, typically 6, total ring atoms, and each aryl group has 6 total ring atoms.
  • the group R" is preferably an alkylene chain, and is preferably linear.
  • Each group R 3 when present, is preferably selected independently from unsubstituted C 1-4 alkyl, unsubstituted C 1-4 alkoxy, fluoro, and chloro.
  • n is 1 or 2
  • each R 3 is independently selected form methyl, methoxy, fluoro, and chloro.
  • n is zero, such that no group R 3 is present.
  • R 8 is hydrogen. In another preferred embodiment, R 8 is a group of the formula:
  • R 9 is hydrogen or C 1-4 alkyl, including hydrogen or methyl. In one embodiment R 9 is hydrogen. In another embodiment, R 9 is methyl.
  • W is CCl. In another embodiment, W is N.
  • Selected embodiments of other variables of formula I include, independently of each other: for X 1 and X 2 , chloro; for R 2 , hydrogen or C 1-4 alkyl; for R 4 and R 5 , hydroxyl and hydrogen, respectively; for R 6 and R 7 , hydrogen and methyl, respectively; and for R 8 , hydrogen.
  • R a is -Y-R"-, where R" is C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene, and Y is selected from a direct bond, NR', O, S, C(O), NR'(CO), and (CO)NR', where R' is hydrogen or methyl.
  • Y is a direct bond.
  • R" is C 1-6 alkylene or, more preferably, C 1-4 alkylene, e.g. methylene, ethylene, propylene or butylene.
  • Y is a direct bond
  • R" is C 1-6 alkylene or, more preferably, C 1-4 alkylene, e.g. methylene.
  • the pyridinium ring in formula I is typically meta or para substituted, more generally para substituted.
  • variable x is 0 or 1.
  • the group R b is preferably selected from the group consisting of hydrogen, C 1-4 alkyl or C 2-4 alkenyl. In one embodiment, R b is hydrogen or C 1-4 alkyl.
  • the group R c when x is not 0, is preferably -Y'-R"-Y'-, where each Y' is independently selected from a direct bond, O, and NR', where R' is hydrogen or methyl, and R" is selected from C 1-12 alkylene, C 2-12 alkenylene, and C 2-12 alkynylene, wherein the alkylene, alkenylene or alkynylene groups are optionally substituted with 1 or 2 groups selected from Z or the side chain of a naturally-occurring amino acid.
  • each Y' is a direct bond
  • R" is C 1-12 alkylene or C 2-12 alkenylene, which may be substituted with 1 or 2 groups selected from Z and a side chain of naturally-occurring amino acid.
  • R" is C 1-12 alkylene, including C 1-6 alkylene, and is unsubstituted or substituted with a -COOH group.
  • the variable y is 0 or 1.
  • the group R d is preferably selected from the group consisting of hydrogen and C 1-4 alkyl, and, in selected embodiments, hydrogen and methyl.
  • R d is H.
  • the group R e when y is not 0, is preferably selected from C 1-12 alkylene, C 2-12 alkenylene, and C 2-12 alkynylene. In one embodiment, R e is C 1-12 alkylene. More preferably, R e is selected from C 1-6 alkylene, C 2-6 alkenylene, and C 2-6 alkynylene, and most preferably from C 2-4 alkenylene and C 1-4 alkylene.
  • R 2 in selected embodiments, is hydrogen or C 1-4 alkyl. In further embodiments, R 2 is hydrogen or methyl; in one embodiment, R 2 is hydrogen.
  • x and y are independently selected from 0 and 1.
  • preferred embodiments include compounds in which the "linker" structure, represented by "L" in Fig. 1 , includes no more than about 30 carbon atoms, excluding the pyridinium ring.
  • One exemplary class of compounds of structure I is that in which: x is 0 or 1; y is 0 or 1; R a is methylene; R b (when x is 1) is hydrogen, methyl, or ethyl; R c (when x is 1) is C 1-12 alkylene, preferably C 1-6 alkylene, e.g. ethylene or n-pentylene (-(CH 2 ) 5 -), which may be substituted with -COOH; R d (when y is 1) is hydrogen; and R e (when y is 1) is ethylene (-CH 2 CH 2 -).
  • Specific embodiments of this class of structure I include the compounds designated herein as Ia, Ib, Ic, Id, Ie, and If .
  • Specific embodiments of this class of structure I include the compounds designated herein as Ib and Ic .
  • a subset of the invention compounds of formula I can also be defined by formula II.
  • W is CCl.
  • R 9 is hydrogen or C 1-4 alkyl, including hydrogen or methyl.
  • R 10 is hydrogen or C 1-6 alkyl, preferably hydrogen or C 1-4 alkyl, including hydrogen, methyl or ethyl. In another embodiment, R 10 is ethyl.
  • R 11 is C 1-10 alkylene, preferably R 11 is C 2-10 alkylene, and more preferably C 2-6 alkylene, e.g. -(CH 2 ) 2 - or -(CH 2 ) 5 -.
  • the pyridinium ring in formula II is typically meta or para substituted, more generally para substituted.
  • Examples of invention compounds in accordance with formula II include those designated herein as Ib and Ic (see Fig. 1 ).
  • the compounds of formulas I and II are believed to inhibit bacterial cell wall biosynthesis, thereby inhibiting the growth of the bacteria or causing lysis of the bacteria. Accordingly, they are useful as antibiotics.
  • compounds of the invention have been found to possess surprising and unexpected potency against gram-positive bacteria, including methicillin-resistant Staphylococci aureus (MRSA) and methicillin-resistant Staphylococci epidermitis (MRSE), as described further below.
  • MRSA methicillin-resistant Staphylococci aureus
  • MRSE methicillin-resistant Staphylococci epidermitis
  • cross-linked glycopeptide - cephalosporin compounds of this invention can be prepared from readily available starting materials, preferably via the intermediate compounds 1 - 5 described herein. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used, as determined by one skilled in the art, unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be readily determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary or desired to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for a particular functional group, as well as suitable conditions for protection and deprotection of such functional groups, are well known in the art.
  • Protecting groups other than those illustrated in the procedures described herein may be used, if desired. For example, numerous protecting groups, and means for their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999 , and references cited therein.
  • the compounds of formula I where y is 0, or, in selected embodiments, the compounds of formula II , are prepared by reacting a glycopeptide of formula 1 : where R 4 - R 8 , X 1 and X 2 are as defined herein, or a salt, or an activated C-terminal carboxyl derivative and/or amine-protected derivative thereof, with a compound of formula 3 or 4 : where W, R 2 , R 3 , R 9 , R a-e , n, x, and y are as defined herein, or a salt or carboxy-protected derivative thereof; to provide a compound of formula I or II , or a salt or protected derivative thereof.
  • Preferred embodiments of 1 , 3 and 4 are as described above.
  • variables in structures 1 , 3 , and/or 4 are defined as follows: n is 0; x is 1; y is 0; R a is CH 2 ; R b is hydrogen or C 1-6 alkyl (as defined for R 10 above); R c is C 1-12 alkylene (as defined for R 11 above); R 2 , R 5 , and R 6 are hydrogen; R 7 is CH 3 ; R 9 is as defined herein; R 4 is OH; and X 1 and X 2 are Cl.
  • the reaction is conducted by coupling glycopeptide 1 , or a salt thereof, with about 0.5 to about 1.5 equivalents, preferably about 0.9 to about 1.1 equivalents, of a compound of formula 3 or 4 , in an inert diluent, such as DMF, using a conventional carboxylic acid - amine (peptide) coupling reagent, as discussed further below.
  • glycopeptide 1 is typically first contacted with the coupling reagent in the presence of an excess, preferably about 1.8 to about 2.2 equivalents, of an amine, such as diisopropylethylamine at a temperature ranging from about -20 °C to about 25 °C, preferably at ambient temperature, for about 0.25 to about 3 hours.
  • an amine such as diisopropylethylamine
  • excess trifluoroacetic acid typically about 2 equivalents
  • reaction is then generally cooled to a temperature of about -20 °C to about 10 °C, preferably to about 0 °C, and intermediate 3 or 4 is added, followed by excess 2,4,6-collidine.
  • This reaction is typically maintained at about 0 °C for about 1 to about 6 hours, or until the reaction is substantially complete.
  • a glycopeptide derivative of formula 2 where R 2 , R 4 - R 8 , R d-e , X 1 and X 2 are as defined herein, or a salt or protected derivative thereof, can be reacted with intermediate of formula 5 , where W, R 3 , R 9 , R a-c , n and x, are as defined herein, or a salt or activated or protected derivative thereof.
  • Preferred embodiments of 2 and 5 are as described above.
  • such a coupling reaction is carried out by reacting a salt of intermediate 2 , such as a trifluoroacetate salt, with about 0.5 to 1.5 equivalents of an activated ester of intermediate 5 , in the presence of a base, such as collidine.
  • a salt of intermediate 2 such as a trifluoroacetate salt
  • R d is hydrogen in this case, so that reaction is favored at the C-terminal primary amine. See, for example, the preparation of Ia illustrated in Fig. 3 and described further in Example 4.
  • Preferred coupling reagents, or activating reagents, for use in these reactions include benzotriazol-1-yloxy tripyrrolidinophosphonium hexafluorophosphate (PyBOP), preferably used in the amount of about 0.5 to 1.5 equivalents, preferably about 0.9 to 1.1 equivalents, in combination with about 0.5 to 1.5 equivalents, preferably about 0.9 to 1.1 equivalents, of 1-hydroxybenzotriazole (HOBT) or 1-hydroxy-7-azabenzotriazole (HOAT).
  • PyBOP benzotriazol-1-yloxy tripyrrolidinophosphonium hexafluorophosphate
  • Suitable coupling reagents include O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU); bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl); diphenylphosphoryl azide (DPPA); diphenylphosphinic chloride; diphenyl chlorophosphate (DPCP) and HOAT; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC); pentafluorophenyl diphenylphosphinate, and the like.
  • HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • BOP-Cl bis(2-oxo-3-oxazolidinyl)phosphin
  • any protecting groups present in the product are then removed using conventional procedures and reagents.
  • deprotection of N-trityl, N-BOC (N- tert -butoxycarbonyl) and/or COO-PMB ( para -methoxybenzyl ester) can be effected by treatment with excess trifluoroacetic acid and excess anisole or triethylsilane in an inert diluent, such as dichloromethane or heptane, at ambient temperature for about 1 to about 12 hours, or until the reaction is complete.
  • the deprotected product can be purified using conventional procedures, such as column chromatography, HPLC, recrystallization and the like.
  • Glycopeptides of formula 1 suitable for use in the above procedure are either commercially available or can be prepared by fermentation of the appropriate glycopeptide-producing organism, followed by isolation of the glycopeptide from the resulting fermentation broth using art recognized procedures and equipment.
  • the derivative 2 is readily prepared by reaction of 1 with a diamine, as described, for example, in Example 3.
  • cephalosporin intermediates 3 and 4 used in the above procedures are readily prepared from commercially available starting materials and reagents using conventional procedures.
  • an intermediate of formula 4 can be prepared as shown in Fig. 2 and described in Examples 1 and 2. Briefly, 2-amino-5-chloro- ⁇ -methoxyimino-4-thiazole acetic acid ( 6 ) was reacted with the amino cephalosporinic ester 7 , catalyzed with EDAC, forming an amide linkage. This product ( 8 ) was then treated with TFA and anisole to cleave the PMB ester, followed by displacement of the primary chloride with a pyridine derivative.
  • the pyridine derivative contains substituents -R a -NHR 2 and optionally substituent(s) R 3 , as shown in structure 4 above.
  • the compound 4-(N-t-BOC-N-ethyl)aminomethyl pyridine ( 9 ) is employed, such that R a is methylene and R 2 is ethyl.
  • This reaction gives the intermediate ( 10 ) in protected form; deprotection with TFA gives the intermediate 4a (intermediate 4 where W is CCl, R 9 is Me, n is 0, R a is CH 2 , and R 2 is Et).
  • the product 8 was reacted with sodium iodide in acetone, followed by reaction with 9 . Reaction with TFA/anisole then was used to remove both the Boc and PMB protecting groups.
  • substituted pyridines for use in the above reactions are either commercially available or can be prepared from commercially available starting materials and reagents using conventional procedures.
  • various aminoalkyl-substituted pyridines are commercially available, e.g. aminomethyl pyridines, where R a is methylene, and aminoethyl pyridines, where R a is ethylene, or can be prepared using standard organic synthesis procedures.
  • Representative substituted pyridine derivatives for use in this reaction include those in which R 3 is selected from methyl, methoxy, thiomethoxy, carboxythiomethoxy, fluoro, chloro, phenyl, cyclopropyl, carboxylic acid, carboxamide, and combinations thereof.
  • starting pyridine compounds are commercially available or can be prepared by well known procedures.
  • 3-hydroxypyridine, 4-hydroxypyridine, 3-aminopyridine, 4-aminopyridine, 4-mercaptopyridine, nicotinic acid and isonicotinic acid are commercially available from Aldrich Chemical Co, Milwaukee, WI.
  • FIG. 4 shows reaction of an intermediate of formula 4 with N-(t-BOC)- ⁇ -alanine (see Example 5, preparation of Ib ) and with aspartic acid (see Example 8, preparation of Ie ) to form intermediates of formula 3 , where x is 1, after deprotection. Further addition(s) of ⁇ -alanine or like compounds, such as other amino acids, could be employed to form intermediates of formula 3 in which x >1.
  • Reaction of intermediate 4 with a diacid e.g. of the structure HOOC-R c -COOH
  • a diacid e.g. of the structure HOOC-R c -COOH
  • suitable activating and/or protecting reagents can be employed (with suitable activating and/or protecting reagents) to form intermediates of formula 5 , in which x is 1 (see Fig. 3 ; Example 4; preparation of Ia ).
  • intermediate 4 would first be reacted with one or more moles of an amino acid (e.g. of the structure HOOC-R-NHR b ).
  • linking moieties including R c will include one or more carbamate or urea linkages, rather than amide linkages.
  • Such linkages can be formed by conventional methods. For example, an amine (such as -NHR 2 in intermediate 3 or 4 ) can be reacted with an isocyanate or a chloroformate to form, respectively, a urea or carbamate linkage.
  • cross-linked glycopeptide - cephalosporin compounds of this invention are typically administered to a patient in the form of a pharmaceutical composition. Accordingly, in one of its composition aspects, this invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof.
  • any conventional carrier or excipient may be used in the pharmaceutical compositions of this invention.
  • the choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of bacterial infection.
  • the preparation of a suitable pharmaceutical composition for a particular mode of administration such as oral, topical, inhaled or parenteral administration, is well within the scope of those skilled in the pharmaceutical arts.
  • the ingredients for such compositions are commercially available from, for example, Sigma, P.O. Box 14508, St. Louis, MO 63178.
  • conventional formulation techniques are described in Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985 ) and " Modern Pharmaceutics," Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds .).
  • compositions of this invention will typically contain a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof.
  • pharmaceutical compositions will contain from about 0.1 to about 90% by weight of the active agent, and more generally from about 10 to about 30% of the active agent.
  • Preferred pharmaceutical compositions of this invention are those suitable for parenteral administration, particularly intravenous administration.
  • Such pharmaceutical compositions typically comprise a sterile, physiologically-acceptable aqueous solution containing a therapeutically effective amount of a compound of formula I or II or a pharmaceutically-acceptable salt thereof.
  • aqueous carrier solutions suitable for intravenous administration of active agents are well known in the art.
  • aqueous solutions include, by way of example, 5% dextrose, Ringer's solutions (lactated Ringer's injection, lactated Ringer's plus 5% dextrose injection, acylated Ringer's injection), Normosol-M, Isolyte E, and the like.
  • such aqueous solutions may contain a co-solvent, for example, polyethylene glycol; a chelating agent, for example, ethylenediamine tetraacetic acid; a solubilizing agent, for example, a cyclodextrin; an anti-oxidant, for example, sodium metabisulphite; and the like.
  • a co-solvent for example, polyethylene glycol
  • a chelating agent for example, ethylenediamine tetraacetic acid
  • a solubilizing agent for example, a cyclodextrin
  • an anti-oxidant for example, sodium metabisulphite
  • the aqueous pharmaceutical compositions of this invention can be lyophilized and subsequently reconstituted with a suitable carrier prior to administration.
  • the pharmaceutical composition is a lyophilized composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula I or II , or a pharmaceutically-acceptable salt thereof.
  • the carrier in this composition comprises sucrose, mannitol, dextrose, dextran, lactose or a combination thereof. More preferably, the carrier comprises sucrose, mannitol, or a combination thereof.
  • the pharmaceutical compositions of this invention contain a cyclodextrin.
  • the cyclodextrin is preferably hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl ether ⁇ -cyclodextrin.
  • the cyclodextrin will comprise about 1 to 25 weight percent; preferably, about 2 to 10 weight percent of the formulation. Additionally, the weight ratio of cyclodextrin to active agent will typically range from about 1:1 to about 10:1.
  • compositions of this invention are preferably packaged in a unit dosage form.
  • unit dosage form refers to a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units.
  • unit dosage forms may be packaged in sterile, hermetically-sealed ampoules and the like.
  • a frozen solution suitable for preparing an injectable solution is prepared as follows: Ingredients Amount Active Compound 10 to 1000 mg Excipients (e.g., dextrose) 0 to 50 g Water for Injection Solution 10 to 100 mL
  • a lyophilized powder suitable for preparing an injectable solution is prepared as follows: Ingredients Amount Active Compound 10 to 1000 mg Excipients (e.g., mannitol and/or sucrose) 0 to 50 g Buffer Agent (e.g., citrate) 0 to 500 mg Water for Injection 10 to 100 mL
  • Excipients e.g., mannitol and/or sucrose
  • Buffer Agent e.g., citrate
  • the excipients and/or buffering agents are dissolved in about 60% of the water for injection.
  • the active compound is added and dissolved and the pH is adjusted with 1 M sodium hydroxide to 3 to 4.5 and the volume is adjusted to 95% of the final volume with water for injection.
  • the pH is checked and adjusted, if necessary, and the volume is adjusted to the final volume with water for injection.
  • the formulation is then sterile filtered through a 0.22 micron filter and placed into a sterile vial under aseptic conditions.
  • the formulation is then freeze-dried using an appropriate lyophilization cycle.
  • the vial is capped (optionally under partial vacuum or dry nitrogen), labeled and stored under refrigeration.
  • the lyophilized powder of Formulation Example B (e.g., containing 10 to 1000 mg of active compound) is reconstituted with 20 mL of sterile water and the resulting solution is further diluted with 80 mL of sterile saline in a 100 mL infusion bag. The diluted solution is then administered to the patient intravenously over 30 to 120 minutes.
  • the cross-linked glycopeptide - cephalosporin compounds of the invention are useful as antibiotics.
  • the compounds of this invention are useful for treating or preventing bacterial infections and other bacteria-related medical conditions in mammals, including humans and their companion animals (i.e., dogs, cats, etc.) that are caused by microorganisms susceptible to the compounds of this invention.
  • the compounds of this invention are particularly useful for treating or preventing infections caused by Gram-positive bacteria and related microorganisms.
  • the compounds of this invention are effective for treating or preventing infections caused by certain Enterococcus spp.; Staphylococcus spp., including coagulase negative staphylococci (CNS); Streptococcus spp.; Listeria spp.; Clostridium ssp.; Bacillus spp.; and the like.
  • Examples of bacterial species effectively treated with the compounds of this invention include, but are not limited to, methicillin-resistant Staphylococcus aureus (MRSA); methicillin-susceptible Staphylococcus aureus (MSSA); glycopeptide intermediate-susceptible Staphylococcus aureus (GISA); methicillin-resistant Staphylococcus epidermitis (MRSE); methicillin-sensitive Staphylococcus epidermitis (MSSE); vancomycin-sensitive Enterococcus faecalis (EFSVS); vancomycin-sensitive Enterococcus faecium (EFMVS); penicillin-resistant Streptococcus pneumoniae (PRSP); Streptococcus pyogenes; and the like.
  • MRSA methicillin-resistant Staphylococcus aureus
  • MSSA methicillin-susceptible Staphylococcus aureus
  • GISA glycopeptide intermediate-susceptible Staphylococcus au
  • vancomycin was bactericidal against MRSA at a concentration of 4 ⁇ g/mL in 24 hours.
  • a compound of formula I i.e. compound Ib
  • the compounds of the invention are preferred for treating or preventing infections caused by strains of bacteria that are susceptible to either glycopeptides or cephalosporins.
  • infections or bacteria-related medical conditions which can be treated or prevented with the compounds of this invention include, but are not limited to, skin and skin structure infections, urinary tract infections, pneumonia, endocarditis, catheter-related blood stream infections, osteomyelitis, and the like.
  • the patient may already be infected with the microorganism to be treated or merely be susceptible to infection in which case the active agent is administered prophylactically.
  • the compounds of this invention are typically administered in a therapeutically effective amount by any acceptable route of administration.
  • the compounds are administered parenterally.
  • the compounds may be administered in a single daily dose or in multiple doses per day.
  • the treatment regimen may require administration over extended periods of time, for example, for several days or for one to six weeks or longer.
  • the amount of active agent administered per dose or the total amount administered will typically be determined by the patient's physician and will depend on such factors as the nature and severity of the infection, the age and general health of the patient, the tolerance of the patient to the active agent, the microorganism(s) causing the infection, the route of administration and the like.
  • suitable doses will range of from about 0.25 to about 10.0 mg/kg/day of active agent, preferably from about 0.5 to about 2 mg/kg/day. For an average 70 kg human, this would amount to about 15 to about 700 mg per day of active agent, or preferably about 35 to about 150 mg per day.
  • the compounds of this invention are effective for inhibiting the growth of bacteria.
  • bacteria are contacted either in vitro or in vivo with a growth-inhibiting amount of a compound of formula I or II or pharmaceutically acceptable salt thereof.
  • a growth-inhibiting amount will range from about 0.008 ⁇ g/mL to about 50 ⁇ g/mL; preferably from about 0.008 ⁇ g/mL to about 25 ⁇ g/mL; and more preferably, from about 0.008 ⁇ g/mL to about 10 ⁇ g/mL.
  • Inhibition of bacterial growth is typically evidenced by a decrease or lack of reproduction by the bacteria and/or by lysis of the bacteria, i.e., by a decrease in colony-forming units in a given volume (i.e., per mL) over a given period of time (i.e., per hour) compared to untreated bacteria.
  • the compounds of this invention are also effective for inhibiting cell wall biosynthesis in bacteria.
  • bacterial are contacted either in vitro or in vivo with a cell wall biosynthesis-inhibiting amount of a compound of formula I or II or pharmaceutically acceptable salt thereof.
  • a cell wall biosynthesis-inhibiting amount will range from about 0.04 ⁇ g/mL to about 50 ⁇ g/mL; preferably from about 0.04 ⁇ g/mL to about 25 ⁇ g/mL; and more preferably, from about 0.04 ⁇ g/mL to about 10 ⁇ g/mL.
  • Inhibition of cell wall biosynthesis in bacteria is typically evidenced by inhibition or lack of growth of the bacteria including lysis of the bacteria.
  • compounds of this invention have been found to have surprising and unexpectedly rapid cidality against certain bacteria, including methicillin-resistant Staphylococci aureus (MRSA) and methicillin-resistant Staphylococci epidermitis (MRSE).
  • MRSA methicillin-resistant Staphylococci aureus
  • MRSE methicillin-resistant Staphylococci epidermitis
  • Reverse-phase HPLC was typically conducted using a C 18 column and (A) 98% water, 2% acetonitrile, 0.1 % TFA, with an increasing gradient (e.g., 0 to about 70%) of (B) 10% water, 90% acetonitrile, 0.1 % TFA, unless otherwise stated.
  • intermediates 4a - 4g are defined as follows. In each of these compounds, n is 0 and R a is -CH 2 -. Cmpd. W R 9 R a subst. R 2 4a C-Cl CH 3 para CH 2 CH 3 4b C-Cl CH 3 para H 4c C-Cl CH 3 meta H 4d C-H CH 3 para H 4e C-H CH 3 meta H 4f N CH 3 para H 4g C-Cl H para H
  • Example 1 Preparation of 4a: (7R)-7-[( Z )-2-(2-Amino-5-chlorothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[((4-(ethylamino)methyl)-1-pyridinio)methyl]-3-cephem-4-carboxylate Bis-trifluoroacetic Acid Salt (see Fig. 2 and 3).
  • step (a) To the solution of the acid 6 in DMF (101.5 g, 250 mmol) from step (a) was added the aminocephalosporonic ester 7 (34 g, 250 mmol). The mixture was cooled to 0 °C, and 33.5 mL (250 mmol) of 2,4,6-collidine was added. To this solution was added 53 g (275 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After 2 hours, the solution was precipitated into 3 L water and filtered. The solids were washed with water (2 x 1L), saturated sodium bicarbonate (500 mL) and water (4 x 500 mL) and dried under vacuum.
  • Acetone 250 mL was added to a mixture of 50 g (85 mmol) chloromethylcephalosporin ester 8 and 13 g (85 mmol) sodium iodide, under nitrogen in the dark. After stirring for 30 minutes, 27 g (130 mmol) of 4-( N - tert -butoxycarbonyl)aminomethyl pyridine and 30 mL acetone were added. After stirring an additional 2 hours, 1.4 L of 0.1 N HCl was added, producing a gummy precipitate. The solvent portion was decanted, and the gummy residue was treated with 800 mL water to give a solid.
  • Example 3 Preparation of 2a : C-Aminoethylamide Vancomycin (Structure 2 where R 2 , R 5 , R 6 , R 8 are H; R 4 is OH; R 7 is Me; X 1 , X 2 are Cl; R d is H; R e is -CH 2 CH 2 -)
  • This product (Fmoc- 2a ) was taken up in 40 mL of DMF and 10 mL of piperidine was added, and the solution was left to stand at room temperature for 20 minutes, then added dropwise to 450 mL acetonitrile, forming a precipitate. The mixture was centrifuged, the acetonitrile decanted, and the residue washed twice with 450 mL of acetonitrile and once with 450 mL of diethyl ether and then air dried.
  • Pyridinium lactam bis-trifluoroacetate 4a (2.4 g), prepared as described in Example 1 above, was dissolved in N , N -dimethylformamide (DMF, 40 mL) under nitrogen and cooled to 0 °C.
  • Dodecanedioic acid bis-1-hydroxy-7-azatriazole ester (7.0 g) was added ( 11 ), followed by 2,4,6-collidine (1.2 mL), and the mixture was stirred for 65 minutes, then added to ethyl acetate (50 mL), and this mixture precipitated into diethyl ether (400 mL).
  • the activated ester lactam 5a was collected by filtration and dried under vacuum, and a portion (14 mg) was dissolved in DMF (122 ⁇ L) and added at 0 °C to a mixture of C-aminoethylamide vancomycin tritrifluoroacetate, 2a (50 mg), prepared as described in Example 3, and 2,4,6-collidine (5.4 ⁇ L) in DMF (500 ⁇ L). The mixture was kept at 0 °C for 20 minutes, then trifluoroacetic acid was added (7.3 ⁇ L). The mixture was kept at -20 °C overnight, then purified by reverse-phase HPLC to give the product Ia . Analytical Data: MS m / z obs. 2252.8, calc. 2252.7.
  • Trifluoroacetic acid 700 ⁇ L
  • water 30 mL
  • the product was purified by reverse-phase HPLC. After lyophilization, the product was treated with 20 mL of 50% trifluoroacetic acid/dichloromethane for 40 minutes.
  • the lactam amine 3a (see Fig. 4 ) was recovered as its bis-trifluoroacetate salt on precipitation into diethyl ether, and dried under vacuum.
  • Vancomycin hydrochloride monohydrate, 1a (900 mg) (Structure 1 where R 5 , R 6 , R 8 are H; R 4 is OH; R 7 is Me; X 1 , X 2 are Cl; also referred to in Figures as "vancomycin”) was dissolved in dimethyl sulfoxide (5mL) under nitrogen at room temperature, and 1-hydroxy-7-azatriazole was added (80 mg), followed by PyBOP (300 mg) in DMF (5 mL) and N , N- diisopropylethylamine (100 ⁇ L). The mixture was stirred for 20 minutes, trifluoroacetic acid (45 ⁇ L) was added, and the mixture was cooled to 0 °C.
  • Vancomycin hydrochloride monohydrate, 1a (900 mg), was dissolved in dimethyl sulfoxide (5 mL) under nitrogen at room temperature, and 1-hydroxy-7-azatriazole was added (80 mg), followed by PyBOP (300mg) in DMF (5 mL) and N , N- diisopropylethylamine (100 ⁇ L). The mixture was stirred for 20 minutes, trifluoroacetic acid (45 ⁇ L) was added, and the mixture was cooled to 0 °C. Pyridinium lactam bis-trifluoroacetate 4c (250 mg) (identical to 4b with the exception of meta substitution on pyridine; see Fig.
  • Vancomycin hydrochloride, 1a (0.32 g, 0.21 mmol), was dissolved in 3 mL of DMSO. A 0.5 mL solution of PyBOP (0.11 g, 0.21 mmol) and HOAT (0.03 g, 0.21 mmol) in DMF was added, followed by DIPEA (0.04 mL, 0.21 mmol). The reaction was stirred 30 minutes, then TFA (0.02 mL, 0.21 mmol) was added, and the mixture was cooled to 0 °C. A solution of 3b (0.15 g, 0.17 mmol) (see Fig. 6 ) in DMF (1 mL) was then added, followed by collidine (0.08 mL, 0.63 mmol).
  • HOAt (0.0626 g, 0.460 mmol) was added to a solution of vancomycin hydrochloride (0.7078 g, 0.455 mmol) in DMSO (3.5 mL).
  • PyBOP (0.2338 g, 0.449 mmol) dissolved in DMF (3.5 mL) and DIPEA (79.0 ⁇ L, 0.453 mmol) were added, and the reaction was stirred at room temperature under nitrogen for 20 minutes, followed by addition of TFA (35.0 ⁇ L, 0.454 mmol). The reaction was then cooled in an ice bath.
  • Lactam amine 4d (0.166 g, 0.227 mmol) was added, and upon dissolution collidine (180.0 ⁇ L, 1.365 mmol) was added. After 50 minutes of stirring, TFA (125.0 ⁇ L, 1.62 mmol) was added, and the product was precipitated with acetonitrile and centrifuged. The pellet was redissolved in a minimal amount of DMF and reprecipitated with acetonitrile three times, then dried under vacuum to give 0.8 g crude product. The crude product was purified by prep HPLC (2-35 acetonitrile/water), and fractions containing compound Ik were collected and lyophilized.
  • HOAt (0.560 g, 4.11 mmol) was added to a solution of vancomycin hydrochloride (6.350 g, 4.08 mmol) in DMSO (30 mL). PyBOP (2.127 g, 4.09 mmol) dissolved in DMF (30 mL) and DIPEA (0.711 mL, 4.08 mmol) were added, and the reaction was stirred at room temperature under nitrogen for 20 minutes, followed by addition of TFA (0.314 mL, 4.08 mmol). The reaction was then cooled in an ice bath.
  • Lactam amine 3c (1.7 g, 2.04 mmol) dissolved in DMSO (25 mL) and DMF (10 mL) was added, and upon dissolution collidine (1.89 mL, 14.3 mmol) was added. The reaction was stirred for 50 minutes, TFA (1.26 mL, 16.3 mmol) was added, and the product was precipitated with acetonitrile and centrifuged down. The pellet was redissolved in a minimal amount of DMF and reprecipitated with acetonitrile three times, then dried under vacuum to give 7.4 g crude product. This crude product was purified by preparative HPLC (2-35 acetonitrile/water), and fractions containing the product, Ig , were collected and lyophilized.
  • Vancomycin hydrochloride (0.73 g, 0.49 mmol) was dissolved in 2.5 mL of DMSO. A solution of PyBOP (0.23 g, 0.45 mmol) and HOAT (0.06 g, 0.45 mmol) was added in 2 mL of DMF, followed by DIPEA (0.16 mL, 0.82 mmol). The reaction was stirred for 25 minutes, then TFA (0.07 mL, 8.2 mmol) was added, and the reaction was cooled to 0 °C. Collidine was added (0.22mL, 1.6 mmol), followed by a solution of the above lactam 4e in 2 mL of DMF. The reaction was stirred for 2 h, then precipitated from ether and centrifuged. The product was purified by HPLC and then lyophilized to yield 0.23 g of the product, Ij.
  • the chloro compound 16 (4.0 g, 7.23 mmol) was placed in a flask with 4-t-BOC-aminomethylpyridine (2.26 g, 10.85 mmol) and sodium iodide (1.08 g, 7.23 mmol) and purged with N 2 .
  • Acetone 60 mL was added, and the reaction mixture was stirred at room temperature for 2 hours, then poured into 300 mL of 0.2 M HCl, resulting in the formation of a red gum on the sides of the flask. The acetone was decanted and the gum was dried under vacuum. Once dry, the residue was dissolved in 20 mL of DCM, and TFA (20 mL) was added.
  • Vancomycin hydrochloride (0.2 g, 0.135 mmol) and HOAt (20.6 mg, 0.135 mmol) were dissolved in 2 mL of DMSO. To this solution was added a solution of PyBOP (70.2 mg, 0.0135 mmol) in 2 mL of DMF. DIPEA (23.5 ⁇ L, 0.135 mmol) was added, and the solution was stirred at room temperature for 20 min. After this time, a solution of 4f (49 mg, 0.0675 mmol) in 1 mL of DMF was added, and the solution was cooled to 0 °C.
  • 1,3,5-Collidine (62.5 ⁇ L, 0.473 mmol) was then added, and the solution was stirred at 0 °C for 45 min.
  • TFA 150 ⁇ L was then added, and the solution was poured into 70 mL of Et 2 O. The resulting precipitate was filtered, washed with Et 2 O and dried under vacuum. The product was purified by reverse-phase HPLC and isolated by lyophilization to afford Im as the tri-TFA salt.
  • TFA (0.026 mL, 0.33 mmol) was added to the reaction mixture, which was then cooled to 0 °C, and collidine (0.097 mL, 0.73 mmol) and a solution of 4g (123 mg, 0.16 mmol) in DMF (1 mL) were then added.
  • the reaction mixture was allowed to warm to room temperature over 4 h, then added portionwise to ethyl acetate (50 mL), and the resulting solid was collected by filtration and purified by preparative HPLC to yield the TFA salt of the product In (174 mg, 46%) as a white solid.
  • aqueous solubility of compounds of the invention was determined using the following procedure.
  • a 5 wt. % dextrose buffer solution at pH 2.2 was prepared by adding 1 mL of 1 N hydrochloric acid (Aldrich) to 99 mL of a 5 wt. % aqueous dextrose solution (Baxter).
  • a 1 mg/mL stock solution for calibration standards was then prepared by dissolving 1 mg of the test compound in 1 mL of DMSO. This solution was vortexed for 30 seconds and then sonicated for 10 minutes. The stock solution was then diluted with water to prepare calibration standards having the following concentrations: 50, 125, 250, 375 and 500 ⁇ g/mL.
  • Each test compound (30 mg) was weighed into a Millipore non-sterile, Ultrafree-MC 0.1 ⁇ m filter unit (Millipore UFC30VVOO) and a magnetic stir bar was added to each unit.
  • the 5 wt. % dextrose buffer solution (750 ⁇ L) was then added to each unit and these mixtures were vortexed for 5 minutes.
  • the filter units were then placed in an Eppendorf tube rack and the tube rack was placed on top of a magnetic stirrer.
  • Each unit was then titrated to pH 3 using 1 N NaOH (VWR) and the resulting solutions centrifuged at 7000 rpm for 5 minutes.
  • Each unit was then diluted 200 fold with 5% dextrose buffer solution and the diluted samples were transferred into auto sampler vials for analysis.
  • the calibration standards and the test samples were analyzed by reverse-phase HPLC using the following conditions:
  • MICs Minimum inhibitory concentration assays were performed using the broth microdilution method set forth in NCCLS guidelines (see, NCCLS. 2000. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Fifth Ed., Vol. 20, No. 2 ). Bacterial strains were obtained from the American Type Tissue Culture Collection (ATCC), Stanford University Hospital (SU), Kaiser Permanente Regional Laboratory in Berkeley (KPB), Massachusetts General Hospital (MGH), the Centers for Disease Control (CDC), the San Francisco Veterans' Administration Hospital (SFVA) or the University of California San Francisco Hospital (UCSF).
  • ATCC American Type Tissue Culture Collection
  • SU Stanford University Hospital
  • KPB Kaiser Permanente Regional Laboratory in Berkeley
  • MGH Massachusetts General Hospital
  • CDC the Centers for Disease Control
  • SFVA San Francisco Veterans' Administration Hospital
  • UCSF University of California San Francisco Hospital
  • Vancomycin-resistant enterococci were phenotyped as Van A or Van B based on their sensitivity to teicoplanin. Some vancomycin-resistant enterococci that had been genotyped as Van A, Van B, Van C1 or Van C2 were also obtained from the Mayo Clinic.
  • cryopreserved bacterial cultures of reference and clinical strains were streaked for isolation on appropriate agar medium (i.e., Trypticase Soy Agar, Trypticase Soy Agar with defibrinated sheep erythrocytes, Brain Heart Infusion Agar, Chocolate Agar). Following incubation to allow formation of colonies, these plates were sealed with Parafilm® and stored refrigerated for up to two weeks.
  • agar medium i.e., Trypticase Soy Agar, Trypticase Soy Agar with defibrinated sheep erythrocytes, Brain Heart Infusion Agar, Chocolate Agar.
  • the broth culture was grown overnight at 35°C, diluted in fresh prewarmed broth and grown to log phase; this is equivalent to a 0.5 MacFarland standard or 1 x 10 8 colony forming units per milliliter (CFU/mL). Not all cell suspensions, due to species variability, contained 1 x 10 8 CFU/mL when turbidity is equivalent to the MacFarland standard, therefore acceptable adjustments (based on NCCLS guidelines) were made in dilutions of different bacterial strains.
  • the inoculum was diluted such that 100 ⁇ L of this culture in Mueller-Hinton Broth, supplemented Mueller-Hinton Broth, or Haemophilus test medium, when over layered onto a 2-fold serially diluted series of antibiotic concentrations also in 100 ⁇ L of corresponding medium, in a 96-well microtiter plate resulted in a starting bacterial concentration of 5 x 10 5 CFU/mL.
  • the plates were then incubated 18-24 hours at 35 °C.
  • the MIC was read visually as the lowest concentration well with no bacterial growth.
  • Bacterial growth is defined as more than three pinpoint colonies, a button of precipitated cells larger than 2 mm in diameter, or obvious turbidity.
  • MSSA methicillin-sensitive Staphylococcus aureus
  • MRSA methicillin-resistant Staphylococcus aureus
  • MRSA methicillin-resistant Staphylococcus aureus
  • MSSE methicillin-sensitive Staphylococcus epidermidis
  • MRSE methicillin-resistant Staphylococcus epidermidis
  • EMVS vancomycin-sensitive Enterococcus faecium
  • ESVS vancomycin-resistant Enterococcus faecalis
  • vancomycin-resistant Enterococcus faecium also resistant to teicoplanin
  • EMVR Van A vancomycin-resistant Enterococcus faecium sensitive to teicoplanin
  • EFMVR Van B vancomycin-resistant Enterococcus faecalis also resistant to teicoplanin
  • ESMVR Van A vancomycin-resistant Enterococcus faecalis sensitive
  • Test compounds having significant activity against the strains mentioned above were then tested for MIC values in a larger panel of clinical isolates including the species listed above as well as non-speciated coagulase negative Staphylococcus both sensitive and resistant to methicillin (MS-CNS and MR-CNS). Additionally, these test compounds were also assayed for MICs against gram-negative microorganisms, such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii, Haemophilius influenzae and Moraxella catarrhalis.
  • gram-negative microorganisms such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii, Haemophilius influenzae and Moraxella catarrhalis.
  • Table 2 shows MIC 90 data for a compound of this invention against methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) as compared to the known antibiotic, vancomycin.
  • Table 2. Minimum Inhibitory Concentrations (MICs), in ⁇ g/mL Compound MIC ( ⁇ g/mL) MRSA 33591 MSSA 13709 Ia 0.13 ⁇ 0.1 Ib ⁇ 0.1 ⁇ 0.1 Ic ⁇ 0.1 ⁇ 0.1 Id ⁇ 0.1 ⁇ 0.1 Ie ⁇ 0.1 ⁇ 0.1 If ⁇ 0.1 ⁇ 0.1 Ig 0.78 ⁇ 0.1 Ij 0.78 ⁇ 0.1 Ik 0.45 ⁇ 0.1 Im ⁇ 0.1 ⁇ 0.1 In ⁇ 0.1 ⁇ 0.1 Vancomycin 2.0 1.0
  • This time-kill assay is a method for measuring the rate of bactericidal activity of a test compound. These procedures are similar to those described in V. Lorian, "Antibiotics in Laboratory Medicine", Fourth Edition, Williams and Wilkins (1996), pages 104-105 . A rapid time-kill is desirable to quickly prevent bacterial colonization and reduce host tissue damage.
  • Bacterial inocula were prepared as described in Example 16 for determination of MIC. Bacteria were diluted in prewarmed media in shake flasks and incubated with shaking (200 rpm, 35 °C). At 0, 1, 4, and 24 hours samples were withdrawn from the flasks and bacteria were enumerated by plate counting. Subsequent to the initial sampling, a compound to be assayed was added to the shake flask culture. Plate counts at these intervals previous to and following addition of the compound were expressed graphically in a time-kill curve. Bactericidal activity is defined as a ⁇ 3 log decrease (reduction greater than or equal to 99.9%) in bacterial cell numbers by 24 hours.
  • a compound of formula I i.e. compound Ib
  • vancomycin was bactericidal against MRSA 33591 at a concentration of 4 ⁇ g/mL in 24 hours.
  • the organism used was either a susceptible or resistant strain of clinically relevant Gram-positive pathogens, such as methicillin-susceptible Staphylococcus aureus (MSSA 13709) and methicillin-resistant Staphylococcus aureus (MRSA 33591).
  • MSSA 13709 methicillin-susceptible Staphylococcus aureus
  • MRSA 33591 methicillin-resistant Staphylococcus aureus
  • the bacterial inoculum concentration was ⁇ 10 6 CFU/mL. Animals were lightly anesthetized with isoflurane and 50 mL of the bacterial inoculum was injected into the anterior thigh. One hour after the inoculation, animals were dosed intravenously with vehicle or the appropriate dose of the test compound.
  • the animals were euthanized (CO 2 asphyxiation) and the anterior and posterior thigh collected aseptically.
  • the thigh was placed into 10 mL sterile saline and homogenized. Dilutions of the homogenate were plated onto triptic soy agar plates which were incubated overnight. The number of bacterial colonies on a given plate was multiplied by the dilution factor, divided by the thigh weight (in grams) and expressed as log CFU/g.
  • ED 50 dose required to produce 50% of the maximum reduction in thigh titre
  • a compound of formula I i.e. compound Ib

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (33)

  1. Composé répondant à la formule I:
    Figure imgb0031
    Figure imgb0032
    ou un de ses sels pharmaceutiquement acceptables, formule dans laquelle :
    chacun des radicaux X1 et X2 représente, de manière indépendante, un atome d'hydrogène ou un atome de chlore ;
    W est choisi parmi un atome d'azote et un groupe CCl ;
    R2 représente un atome d'hydrogène ou un groupe alkyle en C1-C6 ;
    un des radicaux R4 et R5 représente un groupe hydroxyle, l'autre représentant un atome d'hydrogène ;
    chacun des radicaux R6 et R7 représente, de manière indépendante, un atome d'hydrogène ou un groupe méthyle ;
    R8 représente un atome d'hydrogène ou un groupe répondant à la formule :
    Figure imgb0033
    R9 est choisi parmi un atome d'hydrogène, un groupe alkyle en C1-C6, et un groupe cycloalkyle en C3-C6, le groupe alkyle et le groupe cycloalkyle pouvant être substitués avec un groupe -COOH ou avec de 1 à 3 atomes de fluor;
    chaque radical R3 est choisi, de manière indépendante, parmi un groupe alkyle en C1-C6, un groupe -OR, un atome d'halogène, un groupe -SR, un groupe -S(O)R, un groupe -S(O)2R et un groupe -S(O)2OR, chaque radical R représentant, de manière indépendante, un groupe alkyle en C1-C6, qui peut être substitué avec un groupe -COOH ou avec de 1 à 3 atomes de fluor ;
    n est égal à 0, 1, 2 ou 3 ;
    x est égal à 0, 1 ou 2 ;
    y est égal à 0, 1 ou 2 ;
    Ra représente un groupe -Y-R"- où
    R" est choisi parmi un groupe alkylène en C1-C12, un groupe alcénylène en C2-C12, un groupe alcynylène en C2-C12, un groupe cycloalkylène en C3-C6, un groupe arylène en C6-C10, un groupe hétéroarylène en C2-C9, un groupe hétérocyclique en C3-C6, et leurs combinaisons, et est facultativement substitué avec 1 ou 2 groupes choisis parmi un groupe Z, Z étant constitué par un groupe -OR', un groupe -SR', un atome de fluor, un atome de chlore, un groupe -N(R')2, un groupe -OC(O)R', un groupe -CO(O)R', un groupe -NHC(O)R', un groupe -C(O)N(R')2, un groupe -CF3, et un groupe -OCF3, et des chaînes latérales d'acides aminés existants naturellement, chaque radical R' représentant, de manière indépendante, un atome d'hydrogène ou un groupe alkyle en C1-C4; et R" contient au maximum 20 atomes qui ne sont pas des atomes d'hydrogène ;
    Y, qui lie le radical R" au noyau pyridinium en position méta ou en position para, est choisi parmi une liaison directe, un groupe NR', un atome d'oxygène, un atome de soufre, un groupe C(O), un groupe NR'C(O), et un groupe C(O)NR', des liaisons directes entre des hétéroatomes dans Y et R" étant exclues ;
    chacun des radicaux Rb et Rd est choisi, de manière indépendante, parmi le groupe constitué par un atome d'hydrogène, un groupe alkyle en C1-C6, un groupe alcényle en C2-C6, et un groupe alcynyle en C2-C6 ;
    chaque radical Rc représente, de manière indépendante, un groupe -Y'-R"-Y'- dans lequel chaque radical Y' est choisi, de manière indépendante, parmi une liaison directe, un atome d'oxygène et un groupe NR', des liaisons directes entre des hétéroatomes dans Y' et R" étant exclues ; et
    chaque radical Re est choisi, de manière indépendante, parmi R"
  2. Composé selon la revendication 1, dans lequel R9 représente un atome d'hydrogène ou un groupe alkyle en C1-C4
  3. Composé selon la revendication 2, dans lequel R9 représente un atome d'hydrogène ou un groupe méthyle
  4. Composé selon l'une quelconque des revendications 1 à 3, dans lequel W représente un groupe CCl.
  5. Composé selon l'une quelconque des revendications 1 à 3, dans lequel W représente un atome d'azote
  6. Composé selon l'une quelconque des revendications 1 à 5, dans lequel chaque radical R3 est choisi de manière indépendante parmi un groupe alkyle en C1-C4 non substitué, un groupe alcoxy en C1-C4 non substitué, un atome de fluor et un atome de chlore.
  7. Composé selon l'une quelconque des revendications 1 à 6, dans lequel n est égal à 0.
  8. Composé selon l'une quelconque des revendications 1 à 7, dans lequel x est égal à 1 et y est égal à 0
  9. Composé selon la revendication 8, dans lequel R2 représente un groupe -Y-R"- ; Y représente une liaison directe ; et R" représente un groupe alkylène en C1-C6,
  10. Composé selon la revendication 8 ou 9, dans lequel Rc représente un groupe -Y'-R"-Y' ; où chaque radical Y' représente une liaison directe ; et R" représente un groupe alkylène en C1-C12 facultativement substitué avec un groupe -COOH
  11. Composé selon l'une quelconque des revendications 8 à 10, dans lequel Rb représente un atome d'hydrogène ou un groupe alkyle en C1-C4
  12. Composé selon l'une quelconque des revendications 1 à 7, dans lequel x est égal à 1 et y est égal à 1
  13. Composé selon la revendication 12, dans lequel Ra représente un groupe -Y-R"- ; Y représente une liaison directe ; et R" représente un groupe alkylène en C1-C6,
  14. Composé selon la revendication 12 ou 13, dans lequel Rc représente un groupe -Y'-R"-Y' ; où chaque radical Y' représente une liaison directe ; et R" représente un groupe alkylène en C1-C12 facultativement substitué avec un groupe -COOH.
  15. Composé selon l'une quelconque des revendications 12 à 14, dans lequel Re représente un groupe alkylène en C1-C12.
  16. Composé selon l'une quelconque des revendications 12 à 15, dans lequel Rb et Rd représentent de manière indépendante un atome d'hydrogène ou un groupe alkyle en C1-C4.
  17. Composé selon l'une quelconque des revendications 1 à 7, dans lequel x est égal à 0 et y est égal à 0
  18. Composé selon la revendication 17, dans lequel Ra représente un groupe -Y-R"- ; Y représente une liaison directe ; et R" représente un groupe alkylène en C1-C6,
  19. Composé selon l'une quelconque des revendications 1 à 18, dans lequel R2 représente un atome d'hydrogène
  20. Composé selon l'une quelconque des revendications 1 à 4, qui répond à la formule II :
    Figure imgb0034
    ou un de ses sels pharmaceutiquement acceptables ; formule dans laquelle :
    le noyau pyridinium possède une substitution en position méta ou para ;
    R10 représente un atome d'hydrogène ou un groupe alkyle en C1-C6; et
    R11 représente un groupe alkylène en C1-C12
  21. Composé selon la revendication 20, dans lequel R9 représente un atome d'hydrogène
  22. Composé selon la revendication 20, dans lequel R9 représente un groupe méthyle
  23. Composé selon l'une quelconque des revendications 20 à 22, dans lequel le noyau pyridinium est substitué en position para
  24. Composé selon l'une quelconque des revendications 20 à 23, dans lequel R10 représente un atome d'hydrogène ou un groupe alkyle en C1-C4.
  25. Composé selon la revendication 24, dans lequel R10 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle
  26. Composé selon l'une quelconque des revendications 20 à 25, dans lequel R11 représente un groupe alkylène en C1-C10.
  27. Composé selon la revendication 26, dans lequel R11 représente un groupe -(CH2)2- ou un groupe -(CH2)5-.
  28. Composé selon la revendication 20, dans lequel W représente un groupe CCl ; R9 représente un groupe méthyle ; R10 représente un groupe éthyle ; R11 représente un groupe -(CH2)2- ; et le noyau pyridinium est substitué en position para
  29. Composition pharmaceutique comprenant un support pharmaceutiquement acceptable et une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 28
  30. Procédé pour préparer un composé selon l'une quelconque des revendications 1 à 28, le procédé comprenant la mise en réaction d'un composé répondant à la formule 1 :
    Figure imgb0035
     ou d'un de ses sels ou d'un de ses dérivés activés ou protégés, avec un composé répondant à la formule 3 ou 4 :
    Figure imgb0036
    Figure imgb0037
     ou avec un de ses sels ou un de ses dérivés activés ou protégés pour obtenir un composé répondant à la formule I ou un de ses sels
  31. Procédé pour préparer un composé selon l'une quelconque des revendications 1 à 28, le procédé comprenant la mise en réaction d'un composé répondant à la formule 5 :
    Figure imgb0038
     ou d'un de ses sels ou d'un de ses dérivés activés ou protégés, avec un composé répondant à la formule 2 :
    Figure imgb0039
     ou avec un de ses sels ou un de ses dérivés activés ou protégés pour obtenir un composé répondant à la formule I ou un de ses sels
  32. Composé selon l'une quelconque des revendications 1 à 28, à utiliser en thérapie
  33. Utilisation d'un composé selon l'une quelconque des revendications 1 à 28, dans la préparation d'un médicament destiné au traitement d'une infection bactérienne dans un mammifère
EP04752930A 2003-05-23 2004-05-21 Antibiotiques renfermant un compose reticule a base de glycopeptides et de cephalosporine Expired - Lifetime EP1633759B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47306503P 2003-05-23 2003-05-23
PCT/US2004/016007 WO2004113350A1 (fr) 2003-05-23 2004-05-21 Antiobiques renfermant un compose reticule a base de glycopeptides et de cephalosporine

Publications (2)

Publication Number Publication Date
EP1633759A1 EP1633759A1 (fr) 2006-03-15
EP1633759B1 true EP1633759B1 (fr) 2009-12-02

Family

ID=33539049

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04752930A Expired - Lifetime EP1633759B1 (fr) 2003-05-23 2004-05-21 Antibiotiques renfermant un compose reticule a base de glycopeptides et de cephalosporine

Country Status (7)

Country Link
US (4) US7067481B2 (fr)
EP (1) EP1633759B1 (fr)
JP (2) JP2007500222A (fr)
AT (1) ATE450540T1 (fr)
DE (1) DE602004024393D1 (fr)
ES (1) ES2335013T3 (fr)
WO (1) WO2004113350A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
JP4347799B2 (ja) * 2002-05-24 2009-10-21 セラヴァンス， インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
ES2335013T3 (es) * 2003-05-23 2010-03-18 Theravance, Inc. Antibioticos de glucopeptido-cefalosporina reticulados.
ES2302034T3 (es) 2003-07-11 2008-07-01 Theravance, Inc. Antibioticos de cefalosporina-glicopeptido reticulados.
WO2013036783A2 (fr) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Procédés de traitement d'infections intrapulmonaires
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9161990B2 (en) 2013-03-13 2015-10-20 Theravance Biopharma Antibiotics Ip, Llc Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond
MX2020004205A (es) 2013-03-15 2021-11-16 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano.
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
WO2015022335A1 (fr) * 2013-08-12 2015-02-19 Katholieke Universiteit Leuven Analogues de la vancomycine
EP3043797B1 (fr) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Traitement d'infections au moyen de ceftolozane/tazobactam chez des sujets ayant une fonction rénale altérée
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN104341475A (zh) * 2014-10-11 2015-02-11 吉首大学 利奈唑胺-腺苷型多靶点抗菌化合物及其制法和用途
CN104231024B (zh) * 2014-10-11 2016-06-15 吉首大学 噁二唑-肌苷型化合物作为TyrRS抑制剂及其制法和用途
CN104341476A (zh) * 2014-10-11 2015-02-11 吉首大学 利奈唑胺-肌苷型多靶点抗菌化合物及其制法和用途
CN104327140B (zh) * 2014-10-11 2016-06-15 吉首大学 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途
CN104262433B (zh) * 2014-10-11 2016-06-15 吉首大学 噁二唑-腺苷型化合物作为TyrRS抑制剂及其制法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
US4431642A (en) * 1980-12-01 1984-02-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4521413A (en) * 1981-09-14 1985-06-04 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4616081A (en) * 1982-07-07 1986-10-07 Asahi Kasei Kogyo Kabushiki Kaisha Cephalosporin compounds
JPS6041682A (ja) 1983-08-16 1985-03-05 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物及びその製造法
US4921851A (en) 1986-06-09 1990-05-01 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
US4833134A (en) * 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
US5693791A (en) 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
US6518242B1 (en) 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
AU3307399A (en) 1998-02-20 1999-09-06 Advanced Medicine, Inc. Novel antibacterial agents
US6437119B1 (en) 1998-05-07 2002-08-20 William Lawrence Truett Compounds formed from two or three antibiotics and their processes of preparation
EP1085846A2 (fr) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
PT1140993E (pt) 1998-12-23 2003-10-31 Theravance Inc Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
JP4347799B2 (ja) 2002-05-24 2009-10-21 セラヴァンス， インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
ES2335013T3 (es) * 2003-05-23 2010-03-18 Theravance, Inc. Antibioticos de glucopeptido-cefalosporina reticulados.
ES2302034T3 (es) 2003-07-11 2008-07-01 Theravance, Inc. Antibioticos de cefalosporina-glicopeptido reticulados.

Also Published As

Publication number Publication date
JP2007500222A (ja) 2007-01-11
DE602004024393D1 (de) 2010-01-14
ATE450540T1 (de) 2009-12-15
US7332471B2 (en) 2008-02-19
US20040266666A1 (en) 2004-12-30
US20080103299A1 (en) 2008-05-01
EP1633759A1 (fr) 2006-03-15
US7871997B2 (en) 2011-01-18
JP2010254701A (ja) 2010-11-11
US7067481B2 (en) 2006-06-27
US20110224130A1 (en) 2011-09-15
US20060128612A1 (en) 2006-06-15
US8314217B2 (en) 2012-11-20
WO2004113350A1 (fr) 2004-12-29
ES2335013T3 (es) 2010-03-18

Similar Documents

Publication Publication Date Title
US8314217B2 (en) Cross-linked glycopeptide-cephalosporin antibiotics
US7279458B2 (en) Cross-linked glycopeptide-cephalosporin antibiotics
US7601690B2 (en) Cross-linked glycopeptide-cephalosporin antibiotics
US20090137460A1 (en) Cross-linked glycopeptide-cephalosporin antibiotics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051206

Extension state: LT

Payment date: 20051206

17Q First examination report despatched

Effective date: 20071026

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RTI1 Title (correction)

Free format text: CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004024393

Country of ref document: DE

Date of ref document: 20100114

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2335013

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100302

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100402

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

26N No opposition filed

Effective date: 20100903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100603

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004024393

Country of ref document: DE

Representative=s name: OFFICE FREYLINGER S.A., LU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004024393

Country of ref document: DE

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, SOUT, US

Free format text: FORMER OWNER: THERAVANCE, INC., SOUTH SAN FRANCISCO, CALIF., US

Effective date: 20141125

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004024393

Country of ref document: DE

Representative=s name: OFFICE FREYLINGER S.A., LU

Effective date: 20141125

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20141212 AND 20141217

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, US

Effective date: 20150123

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC

Effective date: 20151016

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20180601

Year of fee payment: 15

Ref country code: DE

Payment date: 20180529

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20180528

Year of fee payment: 15

Ref country code: FR

Payment date: 20180525

Year of fee payment: 15

Ref country code: IT

Payment date: 20180522

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180529

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004024393

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190521

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191203

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190521

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190522